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APPENDIX
Shunt Flow Calculation
Shunt flowCOPBF [a]
VO2 (CcO2CvO2)PBF [b]
VO2 (CaO2CvO2)CO [c]
Rearranging equation b gives:
CvO2CcO2VO2 ⁄ PBF
Inserting into equation c gives:
COVO2 ⁄ (CaO2CcO2VO2 ⁄ PBF)
or
CO 1 ⁄ [(CaO2CcO2) ⁄ VO2 1 ⁄ PBF] [d]
Insertion of equation d in equation a gives us the shunt flow
equation:
Shunt flow 1 ⁄ [CaO2CcO2) ⁄ VO2 1 ⁄ PBF]PBF
VO2, CO, PBF, CaO2 and CvO2 were directly measured,
while CcO2 was estimated by assuming pulmonary capillary
O2 saturation  98% and using hemoglobin values obtained
from the arterial blood samples.
Letters to the Editor
Can Perindopril Delay the Onset of Heart
Failure in Duchenne Muscular Dystrophy?
With interest we read the study by Duboc et al. (1) about 57
children with Duchenne muscular dystrophy (DMD) and a left
ventricular ejection fraction (LVEF) 55%. Duboc et al. (1)
conclude that early treatment with perindopril over 60 months
delays both the onset and progression of systolic dysfunction. The
study raises the following concerns:
First, how to explain that within the first 36 months only one
patient in each group developed systolic dysfunction, whereas
within the following 24 months eight patients of group 2 (the
group that received placebo during the first 36 months) deterio-
rated? If the deterioration after 60 months was due to not taking
perindopril during the first 36 months, why did this effect not
become evident earlier? Assuming that perindopril had an effect in
preventing the development of systolic dysfunction in group 1
patients (the group that received perindopril during the first 36
months), it remains unclear whether this was really a drug effect,
selection bias, or whether these patients were less severely affected
when included.
Second, did the eight patients in group 2 with LVEF 45%
after 60 months have a lower baseline LVEF than the remaining
patients? How do the investigators know that it was the lack of
perindopril that led to a decrease in systolic function in these
patients? How could it be excluded that this was not the natural
course? To claim a positive effect of perindopril in patients with
normal systolic function it is not justified to claim a prophylactic
effect of the drug despite a nonsignificant difference in mean values
of LVEF after 60 months. How then to explain the improvement
of LVEF after 36 months in two group 2 patients?
Third, because LVEF decreased under angiotensin-converting
enzyme (ACE) inhibitor therapy in eight patients below 45% and
the mean remained unchanged, there must have been some
patients in whom LVEF has improved. How do the investigators
explain that the drug given during 24 months improved LVEF in
group 2 patients?
Fourth, cardiac function was assessed by resting radionuclide
ventriculography. As most of the DMD patients develop thoraco-
spinal deformities from age 10 on, the accuracy of scintigraphy is
limited (2). Why was no other method, like echocardiography,
applied that would yield additional information about cardiac size
and diastolic function?
Fifth, what was the rationale to give an ACE inhibitor in
patients with normal systolic function? Why was the choice
perindopril, an ACE inhibitor not previously tested in muscular
dystrophy patients (3,4)?
Moreover, information is lacking about the exact neurological
severity of the patients, especially how rapidly neurologic symp-
toms deteriorated, and whether respiratory function changed. How
many patients had or developed rhythm abnormalities? Did the
heart rate increase during follow-up, and was increased heart rate
associated with a decrease of LVEF in any of the patients, suggesting
tachycardiomyopathy (5)? How to explain that 17 patients developed
side effects during placebo therapy? From which drug?
Finally, based on the presented data, it is not justified to propose
perindopril as a prophylactic medication in DMD. To assess left
ventricular function accurately in DMD patients, the application
of at least echocardiography is mandatory (4).
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